Pharmaceuticals

Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination with Cisplatin and Gemcitabine For the First-line Treatment of Patients with recurrent or metastatic NPC

CHENGDU, China, Jan. 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization inChina from National Medical Products Administration (NMPA) for the programmed cell death ligand 1(PD-L1)-directed innovativ...

2025-01-23 13:44 1324

GC Cell Symposium with Bifarma Expands Global Impact and Reach for Immuncell-LC

YONGIN, South Korea, Jan. 23, 2025 /PRNewswire/ -- GC Cell , a leading cell and gene therapy company, announced the successful completion of its first thought leadership symposium in Jakarta, Indonesia. The event was organized in collaboration with PT Bifarma Ad...

2025-01-23 09:30 1325

TraceLink Named to the 2025 RXinsider Pharmacy500 List for Excellence in Pharmacy Supply Chain Innovation

TraceLink recognized for advancing digitalization and orchestration in the pharmacy supply chain, ensuring safe and timely access to medications BOSTON, Jan. 22, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, is honored ...

2025-01-22 23:00 1494

JelloX Aims to Improve Patient-Centered Care with AI-powered 3D Digital Pathology

First shared at a recent Japanese Society of Digital Pathology meeting, the company is forging a global alliance with a leading US medical institution and other organizations to harness technology for better patient care and outcomes in oncology. TAIPEI, Jan. 22, 2025 /PRNewswire/ -- JelloX

2025-01-22 15:29 1407

Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers

HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Today, Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement withArriVent BioPharma, Inc. for MRG007, a Potential Best-in-Class antibody- drug conjugate ("ADC") for the treatment of Gastrointesti...

2025-01-22 12:19 1879

Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

* ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD) study of patients with obesity, supporting once-daily or less frequent oral dosing. * ASC30 oral tablet was generally safe and well ...

2025-01-21 19:00 2277

MedAdvisor Solutions' helps pharmacists in Australia deliver more than 115,000 clinical services to patients through Expanded Scope of Practice Pilots in 2024

New case study showcases improved operational efficiency and patient care with enhanced workflow and clinical services for pharmacists MELBOURNE, Australia, Jan. 21, 2025 /PRNewswire/ -- MedAdvisor Solutions, a global leader in patient engagement and pharmacy technology, published its newest cas...

2025-01-21 07:22 1541

SIRPAD - WORLD'S LARGEST RCT INVESTIGATING MAGICTOUCH PTA SIROLIMUS COATED BALLOON COMPLETES PATIENT ENROLMENT

TAMPA, Fla., Jan. 20, 2025 /PRNewswire/ -- Concept Medical Inc . (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the successful completion of patient enrolment in the SirPAD Trial, with over 1,250 pat...

2025-01-20 21:44 2458

Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...

2025-01-17 08:00 4323

Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference

Advancing into new stage of sustainable growth and global innovation SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines ...

2025-01-17 07:00 3087

Illuccix® Receives European Approval

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent ...

2025-01-17 06:14 3531

Concept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United States

TAMPA, Fla., Jan. 17, 2025 /PRNewswire/ -- Concept Medical Inc. , a global pioneer in innovative drug delivery technology, is proud to announce the successful enrolment of the first patient in the "MAGICAL BTK" (Randomized Controlled Trial of MagicTouch PTA – Siro...

2025-01-17 03:15 2160

SEACare 2025 - Your Gateway to Southeast Asia's Thriving Healthcare Market and Strategic Connections

Unlocking Opportunities in Southeast Asia's Healthcare Market KUALA LUMPUR, Malaysia, Jan. 16, 2025 /PRNewswire/ -- SEACare 2025, the Southeast Asia Healthcare & Pharma Show, returns for its 25th edition from 23 to 25 April 2025 at the Malaysian International Trade and Exhibition Centre (MIT...

2025-01-16 19:56 2455

BGI Genomics Empowers Brunei's National Cervical Cancer Prevention Program

SHENZHEN, China, Jan. 16, 2025 /PRNewswire/ -- On January 15, 2025, the Brunei Ministry of Health (MOH), in partnership with Borneo Genomics Innovation (BGIB), a joint venture of BGI Genomics inBrunei, launched the National Cervical Cancer Prevention and Control Program along with the 2025 Nation...

2025-01-16 12:51 1913

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer

SAN FRANCISCO and SUZHOU, China, Jan. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2025-01-16 08:03 2650

Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference

- The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April - Samsung Biologics to offer ADC services and invest in advanced development and manufacturing capabilities to better address clients' needs INCHEON, South Korea, Jan. 15, 2025 /PRNewswire/ -- Samsung...

2025-01-15 09:40 1731

Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT™ Technology

AT03-65 is the first program utilizing AxcynDOT™, a proprietary payload with a differentiated mechanism of action, to enter clinical development SINGAPORE, Jan. 15, 2025 /PRNewswire/ -- Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in deliveri...

2025-01-15 09:00 1789

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today advises that Dr.Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Confe...

2025-01-14 05:43 1653

BioCina and NovaCina Merger Bolsters Global CDMO Industry

ADELAIDE, South Australia and PERTH, Western Australia, Jan. 14, 2025 /PRNewswire/ -- Global Contract Development and Manufacturing Organizations (CDMOs) BioCina and NovaCina announced a strategic merger that will create a powerful brand in biopharmaceutical and small molecule contract manufactur...

2025-01-14 00:43 1935

Dx&Vx Presents a New Paradigm for Next-Generation Infectious Disease Response with the Development of a Universal Vaccine

- Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine - Based on the Excellent Safety and Immune Response in Phase 1 Clinical Results, with a Plan to Extend Administration Routes and Indications SEOUL, South Korea, Jan. 13, 2025 /PRNe...

2025-01-13 22:00 2277
12345 ... 189